Progress has recently been made toward the production of human skeletal muscle cells from induced pluripotent stem (iPS) cells. However, the functional and ultrastructural characterization, which is crucial for disease modeling and drug discovery, remains to be documented. We show, for the first time to our knowledge, that the electrophysiological properties of human iPS-derived skeletal myocytes are strictly similar to those of their embryonic stem (ES) cell counterparts, and both are typical of aneural mammalian skeletal muscle. In both cell types, intracellular calcium signaling that links membrane depolarization to contraction occurs in the absence of extracellular Ca
2+, a unique feature of skeletal muscle. Detailed analysis of the Ca 2+ signal revealed diverse kinetics of the rising phase, and hence various rates in the release of Ca 2+ from the sarcoplasmic reticulum. This was mirrored by ultrastructural evidence of Ca 2+ release units, which varied in location, shape, and size. Thus, the excitation-contraction coupling machinery of both iPS-and ES-derived skeletal myocytes was functional and specific, but did not reach full maturity in culture. This is in contrast with the myofibrillar network, which displayed the same organization as in adult skeletal muscle. Overall, the present study validates the human iPS-based skeletal myocyte model in comparison with the embryonic system, and provides the functional and ultrastructural basis for its application to human skeletal muscle diseases.human iPS-myocyte | human ES-myocyte | electrophysiology | EC coupling | ultrastructure T he generation of induced pluripotent stem (iPS) cells by genetic reprogramming of adult human somatic cells has opened great opportunities for basic research and regenerative medicine. Modeling human diseases with iPS cell technology offers a direct, noninvasive, and renewable experimental system for reproducing and studying pathological conditions. Within 5-6 y after the first report on human iPS cells (1), an amazing number of diseases affecting various systems (neurological, metabolic, cardiovascular, hematopoietic) have been modeled by reprogramming patient somatic cells (especially skin fibroblasts) into iPS cells followed by specific differentiation into cell types affected by the disease (2). Nevertheless, the efficiency of generating a robust population of cell progenitors from human iPS cells with a high differentiation potential in culture varies widely between different tissues. In particular, producing skeletal muscle cells from iPS cells turned out to be challenging, as reflected by the very limited number of reports and laboratories with successful results. This is in contrast to cardiac muscle, which has widely benefited from iPS cell technology, as various hereditary heart diseases have been modeled and explored (3, 4). We have previously shown that inducible expression of paired box (PAX) 3 or 7 transcription factors in both murine embryonic stem (ES) and iPS cells promotes the production of myogenic progenitors (5, 6)...